Effect of Esterol Tens® Compared to Placebo in Hypercholesterolemic Hypertensive Patients after an Oral Fat Load

Giuseppe Derosa^{1, 2,} , Riccardo Raddino³, Antonio Maggi⁴, Gianfranco Pasini⁵, Angela D’Angelo^{1, 6} and Pamela Maffioli^{1, 7}

¹Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, PAVIA, Italy

²Centre for Prevention, Surveillance, Diagnosis and Treatment of Rare Diseases, Fondazione IRCCS Policlinico San Matteo, PAVIA, Italy;Laboratory of Molecular Medicine, University of Pavia, PAVIA, Italy

³Cardiology Department, University of Brescia, Spedali Civili of Brescia, BRESCIA, Italy

⁴Cardiology Department, Fondazione Poliambulanza, BRESCIA, Italy

⁵Cardiologic Unit, Ospedale di Gavardo, BRESCIA, Italy

⁶Laboratory of Molecular Medicine, University of Pavia, PAVIA, Italy

⁷Centre for Prevention, Surveillance, Diagnosis and Treatment of Rare Diseases, Fondazione IRCCS Policlinico San Matteo, PAVIA, Italy

Cite this paper:
Giuseppe Derosa, Riccardo Raddino, Antonio Maggi, Gianfranco Pasini, Angela D’Angelo and Pamela Maffioli. Effect of Esterol Tens® Compared to Placebo in Hypercholesterolemic Hypertensive Patients after an Oral Fat Load. Journal of Food and Nutrition Research. 2020; 8(4):183-188. doi: 10.12691/jfnr-8-4-4

Abstract

The aim of this study was to compare the response to an oral fat load after three months of adsumption of Esterol Tens® compared to placebo in hypercholesterolemic and hypertensive patients. We enrolled 65 patients and randomized them to take Esterol Tens®, 1 tablet once a day, or placebo for 3 months. We evaluated blood pressure, fasting plasma glucose (FPG), lipid profile, oxidized-low density lipoprotein (Ox-LDL), high sensitivity C-reactive protein (Hs-CRP), soluble vascular cell adhesion protein-1 (sVCAM-1); soluble intercellular adhesion protein-1 (sICAM-1), soluble E-selectin (sE-selectin), myeloperoxidase (MPO). All parameters were assessed at baseline, and after 3 months. In the same visits, an oral fat load was performed. Blood pressure was reduced with nutraceutical both compared to baseline, and placebo. Total cholester, triglycerides, LDL-cholesterol, and Ox-LDL decreased only with the nutraceutical. We observed a decrease of Hs-CRP, and MPO, and an increase of nitrites/nitrates after 3 months both compared to baseline and placebo with the nutraceutical treatment. Values recorded during OFL were lower in the group treated with nutraceutical compared to placebo. The nutraceutical combination improved blood pressure and lipid profile and attenuated the answer to the OFL of lipid profile and, in the same way, improved some inflammatory markers compared to placebo.

Keywords:
dyslipidemia oral fat load nutraceutical

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Hobbs, R., Hoes, A., “Effective management of dyslipidaemia among patients with cardiovascular risk: updated recommendations on identification and follow-up”, Eur J Gen Pract, 11(2), 68-75, 2005.
[2]	Nordestgaard, B.G., Benn, M., Schnohr, P., Tybjaerg-Hansen, A., “Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women”, JAMA, 298(3), 299-308, 2007.
[3]	Karpe, F., Olivecrona, T., Walldius, G., Hamsten, A., “Lipoprotein lipase in plasma after an oral fat load: relation to free fatty acids”, J Lipid Res, 33(7), 975-984, 1992.
[4]	Parks, E.J., “Recent findings in the study of postprandial lipemia”, Curr Atheroscler Rep, 3(6), 462-470, 2001.
[5]	Halkes, C.J., van Dijk, H., de Jaegere, P.P., Plokker, H.W., van Der Helm, Y., Erkelens, D.W., Castro Cabezas, M.. “Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin”, Arterioscler Thromb Vasc Biol, 21(9), 1526-1530, 2001.
[6]	Alipour, A., Elte, J.W., van Zaanen, H.C., Rietveld, A.P., Cabezas, M.C., “Postprandial inflammation and endothelial dysfuction”, Biochem Soc Trans, 35(3), 466-469, 2007.
[7]	Derosa, G., Bonaventura, A., Bianchi, L., Romano, D., Fogari, E., D'Angelo, A., Maffioli, P., “Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients”, Metabolism, 63(7), 957-967, 2014.
[8]	Derosa, G., Cicero, A.F., Fogari, E., D'Angelo, A., Bonaventura, A., Romano, D., Maffioli, P., “Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load”, J Clin Lipidol, 6(6), 553-564, 2012.
[9]	Derosa, G., Ferrari, I., D'Angelo, A., Salvadeo, S.A., Fogari, E., Gravina, A., Mereu, R., Palumbo, I., Maffioli, P., Randazzo, S., Cicero, A.F., “Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects”, Microvasc Res, 80(1), 110-115, 2010.
[10]	Derosa, G., Ferrari, I., D'Angelo, A., Salvadeo, S.A., Fogari, E., Gravina, A., Mereu, R., Palumbo, I., Maffioli, P., Randazzo, S., Cicero, A.F., “Oral fat load effects on inflammation and endothelial stress markers in healthy subjects”, Heart Vessels 24(3), 204-210, 2009.
[11]	Nannoni, G., Alì, A., Di Pierro, F., “Development of a new highly standardized and granulated extract from Monascus purpureus with a high content of Monacolin K and KA and free of inactive secondary Monacolins and citrinin”, Nutrafoods 14, 197-205, 2015.
[12]	Rezaei-Golmisheh, A., Malekinejad, H., Asri-Rezaei, S., Farshid, A.A., Akbari, P., “Hawthorn ethanolic extracts with triterpenoids and flavonoids exert hepatoprotective effects and suppress the hypercholesterolemia-induced oxidative stress in rats”, Iran J Basic Med Sci, 18(7), 691-699, 2015.
[13]	World Health Organization, “Obesity: Preventing and Managing the Global Epidemic. Report of WHO Consultation on Obesity” Geneva: WHO; June 1997.
[14]	Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D.L., Coca, A., de Simone, G., Dominiczak, A., Kahan, T., Mahfoud, F., Redon, J., Ruilope, L., Zanchetti, A., Kerins, M., Kjeldsen, S.E., Kreutz, R., Laurent, S., Lip, G.Y.H., McManus, R., Narkiewicz, K., Ruschitzka, F., Schmieder, R.E., Shlyakhto, E., Tsioufis, C., Aboyans, V., Desormais, I.; Authors/Task Force Members., “2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension”, J Hypertens, 36(10), 1953-2041, 2018.
[15]	Huang, Y., Hu, Y., Mai, W., Cai, X., Song, Y., Wu, Y., Dong, Y., Huang, H., He, Z., Li, W., Yang, Y., Rao, S., “Plasma oxidized low-density lipoprotein is an independent risk factor in young patients with coronary artery disease”, Dis Markers, 31(5), 301, 2011.
[16]	Derosa, G., Catena, G., Raddino, R., Gaudio, G., Maggi, A., D'Angelo, A., Maffioli, P., “Effects on oral fat load of a nutraceutical combination of fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols: A randomized, placebo controlled trial”, Phytomedicine, 42, 75-82, 2018.
[17]	Derosa, G., D'Angelo, A., Romano, D., Maffioli, P., “Effects of a combination of Berberis aristata, Silybum marianum and Monacolin on lipid profile in subjects at low cardiovascular risk; a double-blind, randomized, placebo-controlled trial”, Int J Mol Sci, 18(2), E343, 2017.
[18]	Derosa, G., D'Angelo, A., Salvadeo, S.A., Ferrari, I., Fogari, E., Gravina, A., Mereu, R., Palumbo, I., Maffioli, P., Randazzo, S., Cicero, A.F., “Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects”, Microvasc Res, 79(2), 144-149, 2010.
[19]	Winer, B.J., “Statistical principles in experimental design”, 2nd ed, McGraw-Hill, New York, 1971.
[20]	Derosa, G., Bonaventura, A., Bianchi, L., Romano, D., D'Angelo, A., Fogari, E., Maffioli, P., “Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients”, Expert Opin Biol Ther 13(11), 1495-506, 2013.
[21]	Derosa, G., Bonaventura, A., Bianchi, L., Romano, D., D'Angelo, A., Fogari, E., Maffioli, P., “Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients”, J Biol Regul Homeost Agents, 27(3), 717-728, 2013.
[22]	Cicero, A.F., Derosa, G., Parini, A., Maffioli, P., D'Addato, S., Reggi, A., Giovannini, M., Borghi, C., “Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects”, Nutr Res, 33(8), 622-628, 2013.
[23]	Cicero, A.F., Derosa, G., Manca, M., Bove, M., Borghi, C., Gaddi, A.V., “Different effect of psyllium and guar dietary supplementation on blood pressure control in hypertensive overweight patients: a six-month, randomized clinical trial”, Clin Exp Hypertens, 29(6), 383-394, 2007.
[24]	Derosa, G., Ferrari, I., D'Angelo, A., Salvadeo, S.A., Fogari, E., Gravina, A., Mereu, R., Palumbo, I., Maffioli, P., Randazzo, S., Cicero, A.F., “Oral fat load effects on inflammation and endothelial stress markers in healthy subjects”, Heart Vessels, 24(3), 204-210, 2009.
[25]	Derosa, G., Maffioli, P., Salvadeo, S.A., Ferrari, I., Gravina, A., Mereu, R., Palumbo, I., D'Angelo, A., Cicero, A.F., “Candesartan effect on inflammation in hypertension”, Hypertens Res, 33(3), 209-213, 2010.
[26]	Blüher, M., Unger, R., Rassoul, F., Richter, V., Paschke, R., “Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes”, Diabetologia 45, 210-216, 2002.
[27]	Zwacka, T.P., Hornbach, V., Torzewski, J., “C-reactive protein-mediated lipoprotein uptake by macrophages”, Circulation, 103, 1194-1197, 2001.